Leukine Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing chemotherapy usage, advancements in cytokine therapy development, expansion of oncology and hematology treatment centers, rising survival rates in cancer patients, improved supportive care protocols.

The growth in the forecast period can be attributed to increasing demand for post-chemotherapy immune support, expansion of personalized oncology care, growing investments in immunostimulatory therapies, rising focus on reducing treatment-related complications, increased adoption of biologic supportive therapies. Major trends in the forecast period include increasing use of hematopoietic growth factors in oncology care, rising demand for immune recovery support therapies, growing focus on infection prevention in immunocompromised patients, expansion of supportive cancer care solutions, enhanced optimization of injectable biologic formulations.

The increasing incidence of leukemia is expected to drive the growth of the Leukine market in the future. Leukemia is a type of cancer that affects the blood and bone marrow, leading to the abnormal production of white blood cells. The rising incidence of leukemia can be attributed to factors such as environmental exposures, genetic mutations, lifestyle changes, and advancements in detection methods. Leukine helps leukemia patients by stimulating the production and activation of white blood cells, particularly neutrophils, which enhances their immune response and accelerates recovery following chemotherapy or bone marrow transplantation. This reduces the risk of infection and improves overall treatment outcomes. For example, in 2024, the American Cancer Society reported that the number of leukemia cases in the U.S. increased to 62,770, up from 59,610 in 2023. As a result, the growing incidence of leukemia is fueling the growth of the Leukine market.

A key trend in the Leukine market is the expansion of administration routes to improve patient convenience, enhance compliance, and optimize therapeutic outcomes. This trend aims to offer easier administration options while maintaining the drug’s therapeutic efficacy. For instance, in April 2024, Partner Therapeutics Inc., a U.S.-based biotech company, announced that its partner, Nobelpharma, a Japan-based pharmaceutical company, received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the inhaled use of Leukine (branded as Sargmalin in Japan) to treat autoimmune pulmonary alveolar proteinosis (aPAP). This marks the first regulatory approval for an inhaled recombinant GM-CSF product for this indication, highlighting Leukine's expanding therapeutic applications beyond its traditional uses in oncology and radiation exposure scenarios.

In January 2025, Partner Therapeutics entered into a partnership with the Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2 study of Leukine (sargramostim, rhu GM-CSF). The goal of the partnership is to evaluate safety, determine optimal dosing, and use biomarkers to identify sepsis patients who could benefit from immune-modulatory therapy, thereby expanding Leukine’s clinical indications. BARDA, a U.S.-based agency, focuses on advancing the development of medical countermeasures for public health emergencies.

Major companies operating in the leukine market are Partner Therapeutics Inc.

North America was the largest region in the leukine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukine market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the leukine market by increasing costs of imported biologic raw materials, fermentation inputs, sterile filling equipment, and cold-chain storage systems required for cytokine production. North America and Europe are most affected due to reliance on specialized biologics manufacturing imports, while Asia-Pacific faces cost pressures on branded injectable therapies. These tariffs contribute to higher treatment costs and procurement challenges for oncology centers. However, they also promote domestic biologics manufacturing, regional production scale-up, and investment in localized supportive care pharmaceutical infrastructure.

The leukine market research report is one of a series of new reports that provides leukine market statistics, including leukine industry global market size, regional shares, competitors with a leukine market share, detailed leukine market segments, market trends and opportunities, and any further data you may need to thrive in the leukine industry. This leukine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leukine (sargramostim) is a medication used to stimulate the production of white blood cells, particularly in patients who have undergone chemotherapy or bone marrow transplants. It works by promoting the growth of granulocytes and macrophages, which helps prevent infections in patients with weakened immune systems.

The primary formulations in the Leukine market include injectable formulations, such as lyophilized powder for solution and ready-to-use solutions. Leukine’s injectable formulation consists of a lyophilized powder containing sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The medication is administered via subcutaneous injection or intravenous infusion, depending on the clinical needs. Leukine is used for various indications, including the treatment of acute myeloid leukemia (AML), bone marrow suppression, neutropenia, and as supportive care in cancer patients. The patient demographics for Leukine include adults, pediatric patients, and geriatric individuals. Key end users of the medication include hospitals, oncology clinics, hematology clinics, and research institutions.

The leukine market consists of sales of leukine injections, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.